Table 2. Baseline characteristics of participants in study of bedaquiline treatment for multidrug-resistant tuberculosis*.
| Variable | Cohort |
Total, n = 537 | ||||
|---|---|---|---|---|---|---|
| South Africa, n = 195 | France, n = 45 | Janssen, n = 205 | Armenia, n = 62 | Georgia, n = 30 | ||
| Mean age, y (SD) |
35.8 (11.2) |
37.4 (12.1) |
34.9 (12.2) |
41.6 (12.6) |
38.7 (11.9) |
36.4 (11.8) |
| Sex, no. (%) | ||||||
| M | 98 (50.3) | 36 (80.0) | 132 (64.4) | 55 (88.7) | 21 (70.0) | 342 (63.7) |
| F |
97 (49.7) |
9 (20.0) |
73 (35.6) |
7 (11.3) |
9 (30.0) |
195 (36.3) |
| Mean no. months on BDQ (SD) | 5.8 (1.2) | 12.3 (7.0) | 5.9 (1.1) | 5.6 (1.6) | 6.0 (1.3) | 6.37 (2.3) |
| No. on BDQ >6 mo (%) |
4 (2.1) |
32 (71.1) |
0.0 |
0.0 |
0.0 |
36 (6.7)† |
| Mean total treatment duration, mo (SD) |
14.9 (6.7) |
19.4 (4.7) |
21.8 (7.6) |
20.2(7.4) |
14.0 (6.1) |
18.47 (6.9)† |
| No. (%) with treatment outcome available | 101 (51.8)† | 45 (100.0) | 205 (100.0) | 62 (100.0) | 30 (100.0) | 443 (82.5) |
| No. (%) HIV positive‡ | 120 (63.1) | 2 (4.4) | 8 (4.0) | 4 (6.5) | 1 (3.3) | 135 (25.1) |
| No. (%) on antiretroviral therapy |
110 (56.4) |
2 (4.4) |
0.0 |
0 |
0 |
112 (20.9) |
| Type of TB, no. (%) | ||||||
| Pulmonary | NR | 44 (97.8) | 205 (100.0) | 62 (100.0) | 30 (100.0) | 341 (99.7) |
| Extrapulmonary |
NR |
8 (17.8) |
0 |
0 |
0 |
8 (2.3) |
| No. (%) with previous TB treatment | NR | 34 (75.6) | 193 (94.1) | 62 (100.0) | 29 (96.7) | 271 (79.2) |
| No. (%) with previous second-line TB treatment | NR | 27 (60.0) | 177 (86.3) | 62 (100.0) | 29 (96.7) | 295 (86.3) |
| No. (%) with lung cavities on chest radiograph |
NR |
39 (86.7) |
135 (65.8) |
55 (88.7) |
24 (80.0) |
253 (73.9) |
| Resistance profile, no. (%)§ | ||||||
| MDR TB | 0 | 7 (15.6) | 93 (45.4) | 6 (9.7) | 0 | 100 (18.6) |
| MDR TB + FQ | 73 (37.4) | 8 (17.8) | 31 (15.1) | 26 (41.9) | 5 (16.7) | 147(27.3) |
| MDR TB + INJ | 29 (14.9) | 6 (13.3) | 13 (6.3) | 7 (11.3) | 0 | 55 (10.2) |
| XDR TB | 77 (39.5) | 24 (53.3) | 37 (18.0) | 23 (37.1) | 25 (83.3) | 188 (35.0) |
*BDQ, bedaquiline; FQ, fluoroquinolone; INJ, injectable; MDR, multidrug resistant; NR, not reported; TB, tuberculosis; XDR, extensively drug resistant. †Missing data: South Africa = 15. ‡Missing data: South Africa = 17; Janssen (drug manufacturer) = 7. §Missing data: South Africa = 16; Janssen (drug manufacturer) = 31.